ArticleCancer medicine2026
Macro Habitat-Based T2-Weighted MRI Radiomics and Deep Learning Fusion for Predicting Treatment Response and Prognosis After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multi-habitat radiomics on T2-FS MRI for identifying spatial patterns of axial spondyloarthritis-associated bone marrow edema.Clinical rheumatology · 2026Article
- Radiomic prediction of early progression at 2 years post-treatment in patients with resectable rectal cancer based on rectal tumor and mesentery characteristics: a two-center study.Journal of gastrointestinal oncology · 2026Article
- Article
- Macro Habitat-Based T2-Weighted MRI Radiomics and Deep Learning Fusion for Predicting Treatment Response and Prognosis After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.Cancer medicine · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
backgroundResponse to neoadjuvant chemoradiotherapy (NACRT) in locally advanced rectal cancer (LARC) is highly heterogeneous. Reliable pretreatment prediction of tumor regression and prognosis remains an unmet clinical need to optimize personalized management.
methodsA multicenter retrospective study of 434 Stage II-III LARC patients was conducted across three tertiary hospitals. Pretreatment T2-weighted MRI was used to build intratumoral and peritumoral macrohabitats. Local radiomic features within the tumor were clustered using K-means to generate intratumoral habitats, with the optimal cluster number determined by the Calinski-Harabasz score. Radiomic and 3D deep-learning features from each habitat and the peritumoral region were fused after LASSO-based selection. Machine-learning classifiers (support vector machine, logistic regression, multilayer perceptron) were trained to predict tumor regression grade (TRG). Performance was assessed by ROC and decision-curve analyses, and prognostic value for progression-free survival (PFS) was evaluated using Kaplan-Meier analysis.
resultsThe macro habitat-based fusion model demonstrated superior performance compared with intratumoral, peritumoral, or single-habitat models, achieving AUCs of 0.807-0.830 in the external validation cohort. The derived risk score showed a significant association with progression-free survival (PFS) (p = 0.011 in the training and p = 0.030 in the validation cohorts).
conclusionsThe macro habitat-based MRI radiomics and deep learning fusion model provides a noninvasive, interpretable, and robust biomarker for predicting treatment response and prognosis in LARC. It holds potential to guide personalized therapeutic strategies, including organ-preserving approaches and tailored surveillance after NACRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.